This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Oncology, Other  • Radiation Therapy  • Renal Diseases  • Renal Diseases, Other  • Statistics and Research Methods  • Randomized Controlled Trial  • Drug Therapy  • Drug Therapy, Other  • Gastroenterology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2008;300(4):384-385.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—Recent clinical studies have generated promising results for the treatment of cancers that have traditionally posed significant challenges for oncologists. Findings from trials of experimental therapies for pancreatic, kidney, and endometrial cancer were presented here in June at the annual meeting of the American Society of Clinical Oncology.

A recent clinical trial indicates that gemcitabine, an antimetabolite drug, improves overall survival in patients who have undergone surgery for early stage pancreatic cancer. (Photo credit: Steve Gschmeissner/www.sciencesource.com)

"These studies identify promising new treatments for patients with some of the most hard-to-treat cancers, and new ways to improve patient symptoms and side effects of treatments," said Nicholas Petrelli, MD, medical director of the Helen F. Graham Cancer Center in Wilmington, Del.

PANCREATIC CANCER

One of the studies tackled treatment options for what may be considered the most difficult to treat of all cancers—pancreatic malignancies. Surgery is the only . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?